Cv Sciences, INC 8-K filings

CV Sciences held its 2026 Annual Meeting, electing three directors and ratifying its auditor, but failing to gain shareholder approval for a reverse stock split.

CV Sciences announced its first quarter 2026 financial results, reporting a revenue decrease to $3.2 million from $3.6 million in the prior year, attributed to regulatory challenges.

CV Sciences, Inc. has amended its convertible notes, adjusting the conversion price and extending maturity dates, impacting its financial obligations.

CV Sciences, Inc. reported fiscal year 2025 financial results, highlighting significant improvements in gross margin and adjusted EBITDA, despite a 12.2% decrease in annual revenue.

CV Sciences, Inc. announced its third quarter 2025 financial results, reporting a 16% revenue decrease and a widened adjusted EBITDA loss, while facing new federal hemp industry restrictions.

CV Sciences, Inc. has secured a $600,000 senior secured note, but received only $300,000 in net proceeds after significant discounts and fees, while its auditors issued a 'going concern' opinion.

CV Sciences, Inc. amended its secured promissory note, extending the maturity date to February 2027, restructuring monthly payments, and securing an additional $450,000 in new capital.

CV Sciences, Inc. announced its second quarter 2025 financial results, reporting a decrease in revenue but significant improvements in gross margin and adjusted EBITDA.

CV Sciences, Inc. announced the successful passage of all proposals at its 2025 Annual Meeting, including the re-election of three directors, ratification of its independent auditor, and approval of named executive officer compensation.

CV Sciences, Inc. announced its Q1 2025 financial results, including revenue of $3.6 million and the launch of its new plant-based product line, Lunar Fox.

CV Sciences, Inc. announced its fiscal year-end 2024 financial results, highlighting a slight revenue decrease but significant improvements in gross margins and reduced operating expenses.

CV Sciences enters into a security agreement, pledging its intellectual property to secure a $1.6 million loan.

CV Sciences has initiated arbitration against its former legal counsel, Procopio, Cory, Hargreaves & Savitch LLP, alleging damages resulting from reliance on their advice regarding tax withholding for a former CEO's restricted stock units.

CV Sciences' planned acquisition of Extract Labs has been terminated due to a dispute over bank consent, with CV Sciences disputing the termination and evaluating its options.

CV Sciences has won an arbitration case against former executive Michael J. Mona Jr., with the arbitrator ruling in favor of the company on all claims.

CV Sciences, Inc. has entered into a definitive agreement to acquire Extract Labs, a leading manufacturer of cannabinoid products, for a combination of cash and stock, with potential earnout payments based on future revenue performance.

CV Sciences reported third quarter 2024 financial results, showing stable revenue and progress towards profitability.

CV Sciences maintained consistent revenue in Q2 2024 while improving gross margins and making strategic acquisitions.

CV Sciences has entered into a loan agreement with Streeterville Capital, securing $900,000 in funding through a secured promissory note.

CV Sciences has entered into new three-year employment agreements with CEO Joseph Dowling and CFO Joerg Grasser, replacing their previous contracts.

CV Sciences held its 2024 Annual Meeting, electing three directors and ratifying its independent accounting firm.

CV Sciences reported a slight revenue decrease but improved gross margins in Q1 2024, alongside the acquisition of Elevated Softgels.

CV Sciences has acquired Elevated Softgels, a manufacturer of softgels and tinctures, to in-source production and expand its market reach.

CV Sciences reported its fiscal year 2023 results, highlighting improved gross margins and positive operating cash flow despite a slight revenue decrease.